C
Merck & Co., Inc.
MRK
$103.46
$0.980.96%
C
Hold
8/8/2023Downgrade
Merck & Co., Inc. (MRK) was downgraded to C from B on 8/8/2023 due to a significant decline in the growth index, valuation index and total return index. Earnings per share declined from $1.11 to -$2.3533, and EBIT declined 221.89% from $3.95B to -$4.82B.
Merck & Co., Inc. (MRK) was downgraded to C from B on 8/8/2023 due to a significant decline in the growth index, valuation index and total return index. Earnings per share declined from $1.11 to -$2.3533, and EBIT declined 221.89% from $3.95B to -$4.82B.
B
Buy
4/24/2023Downgrade
Merck & Co., Inc. (MRK) was downgraded to B from B+ on 4/24/2023 due to a decline in the total return index, volatility index and valuation index.
Merck & Co., Inc. (MRK) was downgraded to B from B+ on 4/24/2023 due to a decline in the total return index, volatility index and valuation index.
B
Buy
4/10/2023Downgrade
Merck & Co., Inc. (MRK) was downgraded to B+ from A- on 4/10/2023 due to a noticeable decline in the total return index and valuation index.
Merck & Co., Inc. (MRK) was downgraded to B+ from A- on 4/10/2023 due to a noticeable decline in the total return index and valuation index.
A
Buy
3/14/2023Upgraded
Merck & Co., Inc. (MRK) was upgraded to A- from B+ on 3/14/2023 due to an increase in the total return index, volatility index and valuation index.
Merck & Co., Inc. (MRK) was upgraded to A- from B+ on 3/14/2023 due to an increase in the total return index, volatility index and valuation index.
B
Buy
2/27/2023Downgrade
Merck & Co., Inc. (MRK) was downgraded to B+ from A- on 2/27/2023 due to a decline in the valuation index, growth index and volatility index. Operating cash flow declined 20.92% from $5.6B to $4.43B, EBIT declined 17.94% from $5.15B to $4.22B, and earnings per share declined from $1.28 to $1.1808.
Merck & Co., Inc. (MRK) was downgraded to B+ from A- on 2/27/2023 due to a decline in the valuation index, growth index and volatility index. Operating cash flow declined 20.92% from $5.6B to $4.43B, EBIT declined 17.94% from $5.15B to $4.22B, and earnings per share declined from $1.28 to $1.1808.
A
Buy
2/13/2023Upgraded
Merck & Co., Inc. (MRK) was upgraded to A- from B on 2/13/2023 due to an increase in the total return index and volatility index.
Merck & Co., Inc. (MRK) was upgraded to A- from B on 2/13/2023 due to an increase in the total return index and volatility index.
B
Buy
2/7/2023Downgrade
Merck & Co., Inc. (MRK) was downgraded to B from B+ on 2/7/2023 due to a decline in the total return index.
Merck & Co., Inc. (MRK) was downgraded to B from B+ on 2/7/2023 due to a decline in the total return index.
B
Buy
2/3/2023Downgrade
Merck & Co., Inc. (MRK) was downgraded to B+ from A- on 2/3/2023 due to a large decline in the total return index.
Merck & Co., Inc. (MRK) was downgraded to B+ from A- on 2/3/2023 due to a large decline in the total return index.
A
Buy
1/19/2023Upgraded
Merck & Co., Inc. (MRK) was upgraded to A- from B+ on 1/19/2023 due to a large increase in the total return index.
Merck & Co., Inc. (MRK) was upgraded to A- from B+ on 1/19/2023 due to a large increase in the total return index.
B
Buy
12/12/2022Upgraded
Merck & Co., Inc. (MRK) was upgraded to B+ from B on 12/12/2022 due to a substantial increase in the growth index, total return index and volatility index. Operating cash flow increased 30.22% from $4.3B to $5.6B, and total revenue increased 2.51% from $14.59B to $14.96B.
Merck & Co., Inc. (MRK) was upgraded to B+ from B on 12/12/2022 due to a substantial increase in the growth index, total return index and volatility index. Operating cash flow increased 30.22% from $4.3B to $5.6B, and total revenue increased 2.51% from $14.59B to $14.96B.
B
Buy
5/6/2022Upgraded
Merck & Co., Inc. (MRK) was upgraded to B from B- on 5/6/2022 due to an increase in the volatility index, solvency index and valuation index. The quick ratio increased from 0.79 to 0.9, and debt to equity declined from 0.87 to 0.78.
Merck & Co., Inc. (MRK) was upgraded to B from B- on 5/6/2022 due to an increase in the volatility index, solvency index and valuation index. The quick ratio increased from 0.79 to 0.9, and debt to equity declined from 0.87 to 0.78.
B
Buy
5/3/2022Downgrade
Merck & Co., Inc. (MRK) was downgraded to B- from B on 5/3/2022 due to a decline in the volatility index and valuation index.
Merck & Co., Inc. (MRK) was downgraded to B- from B on 5/3/2022 due to a decline in the volatility index and valuation index.
B
Buy
4/18/2022Upgraded
Merck & Co., Inc. (MRK) was upgraded to B from B- on 4/18/2022 due to an increase in the volatility index and total return index.
Merck & Co., Inc. (MRK) was upgraded to B from B- on 4/18/2022 due to an increase in the volatility index and total return index.
B
Buy
3/28/2022Upgraded
Merck & Co., Inc. (MRK) was upgraded to B- from C+ on 3/28/2022 due to a substantial increase in the valuation index, solvency index and total return index.
Merck & Co., Inc. (MRK) was upgraded to B- from C+ on 3/28/2022 due to a substantial increase in the valuation index, solvency index and total return index.
C
Hold
2/17/2022Downgrade
Merck & Co., Inc. (MRK) was downgraded to C+ from B- on 2/17/2022 due to a decline in the volatility index and total return index.
Merck & Co., Inc. (MRK) was downgraded to C+ from B- on 2/17/2022 due to a decline in the volatility index and total return index.
B
Buy
11/11/2021Upgraded
Merck & Co., Inc. (MRK) was upgraded to B- from C+ on 11/11/2021 due to a significant increase in the growth index, valuation index and volatility index. Earnings per share increased from $0.6099 to $1.8, EBIT increased 33.06% from $3.85B to $5.12B, and total revenue increased 15.37% from $11.4B to $13.15B.
Merck & Co., Inc. (MRK) was upgraded to B- from C+ on 11/11/2021 due to a significant increase in the growth index, valuation index and volatility index. Earnings per share increased from $0.6099 to $1.8, EBIT increased 33.06% from $3.85B to $5.12B, and total revenue increased 15.37% from $11.4B to $13.15B.
C
Hold
11/3/2021Upgraded
Merck & Co., Inc. (MRK) was upgraded to C+ from C on 11/3/2021 due to a noticeable increase in the volatility index, solvency index and total return index.
Merck & Co., Inc. (MRK) was upgraded to C+ from C on 11/3/2021 due to a noticeable increase in the volatility index, solvency index and total return index.
C
Hold
10/18/2021Downgrade
Merck & Co., Inc. (MRK) was downgraded to C from C+ on 10/18/2021 due to a decline in the volatility index, valuation index and dividend index.
Merck & Co., Inc. (MRK) was downgraded to C from C+ on 10/18/2021 due to a decline in the volatility index, valuation index and dividend index.
C
Hold
10/1/2021Upgraded
Merck & Co., Inc. (MRK) was upgraded to C+ from C on 10/1/2021 due to an increase in the volatility index, valuation index and dividend index.
Merck & Co., Inc. (MRK) was upgraded to C+ from C on 10/1/2021 due to an increase in the volatility index, valuation index and dividend index.
C
Hold
9/8/2021Downgrade
Merck & Co., Inc. (MRK) was downgraded to C from C+ on 9/8/2021 due to a large decline in the growth index, solvency index and valuation index. Earnings per share declined from $1.2509 to $0.6099, and operating cash flow declined 19.65% from $1.79B to $1.44B.
Merck & Co., Inc. (MRK) was downgraded to C from C+ on 9/8/2021 due to a large decline in the growth index, solvency index and valuation index. Earnings per share declined from $1.2509 to $0.6099, and operating cash flow declined 19.65% from $1.79B to $1.44B.
C
Hold
5/7/2021Upgraded
Merck & Co., Inc. (MRK) was upgraded to C+ from C on 5/7/2021 due to a significant increase in the growth index, solvency index and dividend index. Earnings per share increased from -$0.8303 to $1.25, EBIT increased 16.04% from $3.3B to $3.83B, and debt to equity declined from 1.27 to 1.16.
Merck & Co., Inc. (MRK) was upgraded to C+ from C on 5/7/2021 due to a significant increase in the growth index, solvency index and dividend index. Earnings per share increased from -$0.8303 to $1.25, EBIT increased 16.04% from $3.3B to $3.83B, and debt to equity declined from 1.27 to 1.16.
C
Hold
4/22/2021Downgrade
Merck & Co., Inc. (MRK) was downgraded to C from C+ on 4/22/2021 due to a decline in the volatility index, total return index and valuation index.
Merck & Co., Inc. (MRK) was downgraded to C from C+ on 4/22/2021 due to a decline in the volatility index, total return index and valuation index.
C
Hold
4/7/2021Upgraded
Merck & Co., Inc. (MRK) was upgraded to C+ from C on 4/7/2021 due to an increase in the volatility index.
Merck & Co., Inc. (MRK) was upgraded to C+ from C on 4/7/2021 due to an increase in the volatility index.
C
Hold
3/23/2021Downgrade
Merck & Co., Inc. (MRK) was downgraded to C from C+ on 3/23/2021 due to a decline in the volatility index, valuation index and dividend index.
Merck & Co., Inc. (MRK) was downgraded to C from C+ on 3/23/2021 due to a decline in the volatility index, valuation index and dividend index.
C
Hold
3/1/2021Downgrade
Merck & Co., Inc. (MRK) was downgraded to C+ from B on 3/1/2021 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $1.16 to -$0.8303, debt to equity increased from 0.98 to 1.27, and EBIT declined 25.92% from $4.46B to $3.3B.
Merck & Co., Inc. (MRK) was downgraded to C+ from B on 3/1/2021 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $1.16 to -$0.8303, debt to equity increased from 0.98 to 1.27, and EBIT declined 25.92% from $4.46B to $3.3B.
B
Buy
11/16/2020Upgraded
Merck & Co., Inc. (MRK) was upgraded to B from B- on 11/16/2020 due to an increase in the growth index, valuation index and total return index. EBIT increased 30.37% from $3.42B to $4.46B, and total revenue increased 15.44% from $10.87B to $12.55B.
Merck & Co., Inc. (MRK) was upgraded to B from B- on 11/16/2020 due to an increase in the growth index, valuation index and total return index. EBIT increased 30.37% from $3.42B to $4.46B, and total revenue increased 15.44% from $10.87B to $12.55B.
B
Buy
10/26/2020Downgrade
Merck & Co., Inc. (MRK) was downgraded to B- from B on 10/26/2020 due to a decline in the total return index.
Merck & Co., Inc. (MRK) was downgraded to B- from B on 10/26/2020 due to a decline in the total return index.
B
Buy
9/30/2020Upgraded
Merck & Co., Inc. (MRK) was upgraded to B from B- on 9/30/2020 due to an increase in the total return index, volatility index and solvency index. The quick ratio increased from 0.68 to 0.86.
Merck & Co., Inc. (MRK) was upgraded to B from B- on 9/30/2020 due to an increase in the total return index, volatility index and solvency index. The quick ratio increased from 0.68 to 0.86.
B
Buy
7/6/2020Upgraded
Merck & Co., Inc. (MRK) was upgraded to B- from C+ on 7/6/2020 due to an increase in the volatility index, valuation index and solvency index.
Merck & Co., Inc. (MRK) was upgraded to B- from C+ on 7/6/2020 due to an increase in the volatility index, valuation index and solvency index.
C
Hold
5/11/2020Downgrade
Merck & Co., Inc. (MRK) was downgraded to C+ from B- on 5/11/2020 due to a decline in the volatility index, valuation index and total return index.
Merck & Co., Inc. (MRK) was downgraded to C+ from B- on 5/11/2020 due to a decline in the volatility index, valuation index and total return index.
B
Buy
3/23/2020Downgrade
Merck & Co., Inc. (MRK) was downgraded to B- from B on 3/23/2020 due to a large decline in the volatility index and total return index.
Merck & Co., Inc. (MRK) was downgraded to B- from B on 3/23/2020 due to a large decline in the volatility index and total return index.
B
Buy
12/18/2019Downgrade
Merck & Co., Inc. (MRK) was downgraded to B from B+ on 12/18/2019 due to a decline in the volatility index, valuation index and growth index. Earnings per share declined from $1.03 to $0.74.
Merck & Co., Inc. (MRK) was downgraded to B from B+ on 12/18/2019 due to a decline in the volatility index, valuation index and growth index. Earnings per share declined from $1.03 to $0.74.
B
Buy
10/3/2019Downgrade
Merck & Co., Inc. (MRK) was downgraded to B+ from A- on 10/3/2019 due to a decline in the total return index.
Merck & Co., Inc. (MRK) was downgraded to B+ from A- on 10/3/2019 due to a decline in the total return index.
A
Buy
8/14/2019Upgraded
Merck & Co., Inc. (MRK) was upgraded to A- from B+ on 8/14/2019 due to an increase in the total return index and volatility index.
Merck & Co., Inc. (MRK) was upgraded to A- from B+ on 8/14/2019 due to an increase in the total return index and volatility index.
B
Buy
8/8/2019Upgraded
Merck & Co., Inc. (MRK) was upgraded to B+ from B on 8/8/2019 due to a large increase in the growth index, volatility index and valuation index. Operating cash flow increased 130.84% from $1.34B to $3.08B, EBIT increased 12.3% from $3.54B to $3.98B, and total revenue increased 8.73% from $10.82B to $11.76B.
Merck & Co., Inc. (MRK) was upgraded to B+ from B on 8/8/2019 due to a large increase in the growth index, volatility index and valuation index. Operating cash flow increased 130.84% from $1.34B to $3.08B, EBIT increased 12.3% from $3.54B to $3.98B, and total revenue increased 8.73% from $10.82B to $11.76B.
B
Buy
6/10/2019Upgraded
Merck & Co., Inc. (MRK) was upgraded to B from B- on 6/10/2019 due to an increase in the valuation index, solvency index and volatility index. The quick ratio increased from 0.72 to 0.89.
Merck & Co., Inc. (MRK) was upgraded to B from B- on 6/10/2019 due to an increase in the valuation index, solvency index and volatility index. The quick ratio increased from 0.72 to 0.89.
B
Buy
4/23/2019Downgrade
Merck & Co., Inc. (MRK) was downgraded to B- from B on 4/23/2019 due to a large decline in the total return index, growth index and volatility index.
Merck & Co., Inc. (MRK) was downgraded to B- from B on 4/23/2019 due to a large decline in the total return index, growth index and volatility index.
B
Buy
3/4/2019Upgraded
Merck & Co., Inc. (MRK) was upgraded to B from B- on 3/4/2019 due to a major increase in the valuation index, total return index and growth index. Operating cash flow increased 28.61% from $2.79B to $3.59B, and total revenue increased 1.89% from $10.79B to $11B.
Merck & Co., Inc. (MRK) was upgraded to B from B- on 3/4/2019 due to a major increase in the valuation index, total return index and growth index. Operating cash flow increased 28.61% from $2.79B to $3.59B, and total revenue increased 1.89% from $10.79B to $11B.
B
Buy
11/8/2018Upgraded
Merck & Co., Inc. (MRK) was upgraded to B- from C on 11/8/2018 due to a significant increase in the growth index, total return index and volatility index. Earnings per share increased from $0.63 to $0.73, EBIT increased 4.49% from $2.81B to $2.94B, and total revenue increased 3.14% from $10.47B to $10.79B.
Merck & Co., Inc. (MRK) was upgraded to B- from C on 11/8/2018 due to a significant increase in the growth index, total return index and volatility index. Earnings per share increased from $0.63 to $0.73, EBIT increased 4.49% from $2.81B to $2.94B, and total revenue increased 3.14% from $10.47B to $10.79B.
C
Hold
6/21/2018Upgraded
Merck & Co., Inc. (MRK) was upgraded to C from C- on 6/21/2018 due to a noticeable increase in the volatility index and growth index. Earnings per share increased from -$0.3874 to $0.27.
Merck & Co., Inc. (MRK) was upgraded to C from C- on 6/21/2018 due to a noticeable increase in the volatility index and growth index. Earnings per share increased from -$0.3874 to $0.27.
C
Hold
12/20/2017Downgrade
Merck & Co., Inc. (MRK) was downgraded to C- from C on 12/20/2017 due to a decline in the volatility index, total return index and solvency index.
Merck & Co., Inc. (MRK) was downgraded to C- from C on 12/20/2017 due to a decline in the volatility index, total return index and solvency index.
C
Hold
11/9/2017Downgrade
Merck & Co., Inc. (MRK) was downgraded to C from B- on 11/9/2017 due to a significant decline in the growth index, valuation index and volatility index. Operating cash flow declined 135.3% from $3.32B to -$1.17B, earnings per share declined from $0.71 to -$0.0205, and EBIT declined 80.03% from $2.75B to $550M.
Merck & Co., Inc. (MRK) was downgraded to C from B- on 11/9/2017 due to a significant decline in the growth index, valuation index and volatility index. Operating cash flow declined 135.3% from $3.32B to -$1.17B, earnings per share declined from $0.71 to -$0.0205, and EBIT declined 80.03% from $2.75B to $550M.
B
Buy
10/27/2017Downgrade
Merck & Co., Inc. (MRK) was downgraded to B- from B on 10/27/2017 due to a noticeable decline in the volatility index and total return index.
Merck & Co., Inc. (MRK) was downgraded to B- from B on 10/27/2017 due to a noticeable decline in the volatility index and total return index.
B
Buy
8/10/2017Upgraded
Merck & Co., Inc. (MRK) was upgraded to B from B- on 8/10/2017 due to a substantial increase in the growth index, volatility index and valuation index. Operating cash flow increased 1,059.79% from $286M to $3.32B, earnings per share increased from $0.56 to $0.71, and EBIT increased 17.09% from $2.35B to $2.75B.
Merck & Co., Inc. (MRK) was upgraded to B from B- on 8/10/2017 due to a substantial increase in the growth index, volatility index and valuation index. Operating cash flow increased 1,059.79% from $286M to $3.32B, earnings per share increased from $0.56 to $0.71, and EBIT increased 17.09% from $2.35B to $2.75B.
B
Buy
5/18/2017Upgraded
Merck & Co., Inc. (MRK) was upgraded to B- from C+ on 5/18/2017 due to a noticeable increase in the growth index, valuation index and volatility index. Earnings per share increased from -$0.2143 to $0.56.
Merck & Co., Inc. (MRK) was upgraded to B- from C+ on 5/18/2017 due to a noticeable increase in the growth index, valuation index and volatility index. Earnings per share increased from -$0.2143 to $0.56.
C
Hold
3/3/2017Downgrade
Merck & Co., Inc. (MRK) was downgraded to C+ from B on 3/3/2017 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.78 to -$0.2143, EBIT declined 121.56% from $3.12B to -$673M, and debt to equity increased from 0.57 to 0.62.
Merck & Co., Inc. (MRK) was downgraded to C+ from B on 3/3/2017 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.78 to -$0.2143, EBIT declined 121.56% from $3.12B to -$673M, and debt to equity increased from 0.57 to 0.62.
B
Buy
3/1/2017Upgraded
Merck & Co., Inc. (MRK) was upgraded to B from B- on 3/1/2017 due to an increase in the total return index.
Merck & Co., Inc. (MRK) was upgraded to B from B- on 3/1/2017 due to an increase in the total return index.
B
Buy
2/6/2017Downgrade
Merck & Co., Inc. (MRK) was downgraded to B- from B on 2/6/2017 due to a decline in the valuation index and dividend index.
Merck & Co., Inc. (MRK) was downgraded to B- from B on 2/6/2017 due to a decline in the valuation index and dividend index.
B
Buy
1/17/2017Upgraded
Merck & Co., Inc. (MRK) was upgraded to B from B- on 1/17/2017 due to an increase in the total return index.
Merck & Co., Inc. (MRK) was upgraded to B from B- on 1/17/2017 due to an increase in the total return index.
B
Buy
12/27/2016Downgrade
Merck & Co., Inc. (MRK) was downgraded to B- from B on 12/27/2016 due to a decline in the total return index, valuation index and dividend index.
Merck & Co., Inc. (MRK) was downgraded to B- from B on 12/27/2016 due to a decline in the total return index, valuation index and dividend index.
B
Buy
11/9/2016Upgraded
Merck & Co., Inc. (MRK) was upgraded to B from B- on 11/9/2016 due to a large increase in the growth index, total return index and valuation index. Operating cash flow increased 83.96% from $1.62B to $2.97B, earnings per share increased from $0.43 to $0.78, and EBIT increased 42.25% from $2.19B to $3.12B.
Merck & Co., Inc. (MRK) was upgraded to B from B- on 11/9/2016 due to a large increase in the growth index, total return index and valuation index. Operating cash flow increased 83.96% from $1.62B to $2.97B, earnings per share increased from $0.43 to $0.78, and EBIT increased 42.25% from $2.19B to $3.12B.
B
Buy
8/10/2016Upgraded
Merck & Co., Inc. (MRK) was upgraded to B- from C+ on 8/10/2016 due to a noticeable increase in the growth index, volatility index and total return index. Earnings per share increased from $0.4 to $0.43, total revenue increased 5.71% from $9.31B to $9.84B, and EBIT increased 0.6% from $2.18B to $2.19B.
Merck & Co., Inc. (MRK) was upgraded to B- from C+ on 8/10/2016 due to a noticeable increase in the growth index, volatility index and total return index. Earnings per share increased from $0.4 to $0.43, total revenue increased 5.71% from $9.31B to $9.84B, and EBIT increased 0.6% from $2.18B to $2.19B.
C
Hold
5/11/2016Upgraded
Merck & Co. Inc. (MRK) was upgraded to C+ from C on 5/11/2016 due to a noticeable increase in the growth index, total return index and solvency index. EBIT increased 27.62% from $1.71B to $2.18B, earnings per share increased from $0.3395 to $0.4, and the quick ratio increased from 1.04 to 1.13.
Merck & Co. Inc. (MRK) was upgraded to C+ from C on 5/11/2016 due to a noticeable increase in the growth index, total return index and solvency index. EBIT increased 27.62% from $1.71B to $2.18B, earnings per share increased from $0.3395 to $0.4, and the quick ratio increased from 1.04 to 1.13.
C
Hold
3/7/2016Downgrade
Merck & Co. Inc. (MRK) was downgraded to C from C+ on 3/7/2016 due to a decline in the total return index, solvency index and valuation index.
Merck & Co. Inc. (MRK) was downgraded to C from C+ on 3/7/2016 due to a decline in the total return index, solvency index and valuation index.
C
Hold
3/1/2016Downgrade
Merck & Co. Inc. (MRK) was downgraded to C+ from B- on 3/1/2016 due to a significant decline in the valuation index, growth index and solvency index. Earnings per share declined from $0.64 to $0.3395, EBIT declined 29.09% from $2.41B to $1.71B, and debt to equity increased from 0.58 to 0.59.
Merck & Co. Inc. (MRK) was downgraded to C+ from B- on 3/1/2016 due to a significant decline in the valuation index, growth index and solvency index. Earnings per share declined from $0.64 to $0.3395, EBIT declined 29.09% from $2.41B to $1.71B, and debt to equity increased from 0.58 to 0.59.
B
Buy
1/25/2016Downgrade
Merck & Co. Inc. (MRK) was downgraded to B- from B on 1/25/2016 due to a decline in the total return index and solvency index.
Merck & Co. Inc. (MRK) was downgraded to B- from B on 1/25/2016 due to a decline in the total return index and solvency index.
B
Buy
11/18/2015Upgraded
Merck & Co. Inc. (MRK) was upgraded to B from B- on 11/18/2015 due to an increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.24 to $0.64, operating cash flow increased 27.85% from $2.59B to $3.31B, and EBIT increased 13.41% from $2.13B to $2.41B.
Merck & Co. Inc. (MRK) was upgraded to B from B- on 11/18/2015 due to an increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.24 to $0.64, operating cash flow increased 27.85% from $2.59B to $3.31B, and EBIT increased 13.41% from $2.13B to $2.41B.
B
Buy
10/28/2015Downgrade
Merck & Co. Inc. (MRK) was downgraded to B- from B on 10/28/2015 due to a large decline in the volatility index, total return index and valuation index.
Merck & Co. Inc. (MRK) was downgraded to B- from B on 10/28/2015 due to a large decline in the volatility index, total return index and valuation index.
B
Buy
7/22/2015Downgrade
Merck & Co. Inc. (MRK) was downgraded to B from B+ on 7/22/2015 due to a decline in the total return index and valuation index.
Merck & Co. Inc. (MRK) was downgraded to B from B+ on 7/22/2015 due to a decline in the total return index and valuation index.
B
Buy
6/30/2015Upgraded
Merck & Co. Inc. (MRK) was upgraded to B+ from B on 6/30/2015 due to an increase in the valuation index and dividend index.
Merck & Co. Inc. (MRK) was upgraded to B+ from B on 6/30/2015 due to an increase in the valuation index and dividend index.
B
Buy
6/15/2015Downgrade
Merck & Co. Inc. (MRK) was downgraded to B from B+ on 6/15/2015 due to a decline in the volatility index and total return index.
Merck & Co. Inc. (MRK) was downgraded to B from B+ on 6/15/2015 due to a decline in the volatility index and total return index.
B
Buy
5/27/2015Upgraded
Merck & Co. Inc. (MRK) was upgraded to B+ from B on 5/27/2015 due to an increase in the volatility index and valuation index.
Merck & Co. Inc. (MRK) was upgraded to B+ from B on 5/27/2015 due to an increase in the volatility index and valuation index.
B
Buy
5/12/2015Downgrade
Merck & Co. Inc. (MRK) was downgraded to B from B+ on 5/12/2015 due to a decline in the volatility index, valuation index and solvency index. Debt to equity increased from 0.44 to 0.63, and the quick ratio declined from 1.19 to 1.09.
Merck & Co. Inc. (MRK) was downgraded to B from B+ on 5/12/2015 due to a decline in the volatility index, valuation index and solvency index. Debt to equity increased from 0.44 to 0.63, and the quick ratio declined from 1.19 to 1.09.
B
Buy
4/28/2015Upgraded
Merck & Co. Inc. (MRK) was upgraded to B+ from B on 4/28/2015 due to an increase in the volatility index.
Merck & Co. Inc. (MRK) was upgraded to B+ from B on 4/28/2015 due to an increase in the volatility index.
B
Buy
3/16/2015Downgrade
Merck & Co. Inc. (MRK) was downgraded to B from B+ on 3/16/2015 due to a decline in the volatility index.
Merck & Co. Inc. (MRK) was downgraded to B from B+ on 3/16/2015 due to a decline in the volatility index.
B
Buy
2/27/2015Upgraded
Merck & Co. Inc. (MRK) was upgraded to B+ from B on 2/27/2015 due to a substantial increase in the valuation index, solvency index and dividend index. The quick ratio increased from 0.8 to 1.19, and debt to equity declined from 0.62 to 0.44.
Merck & Co. Inc. (MRK) was upgraded to B+ from B on 2/27/2015 due to a substantial increase in the valuation index, solvency index and dividend index. The quick ratio increased from 0.8 to 1.19, and debt to equity declined from 0.62 to 0.44.
B
Buy
12/4/2014Downgrade
Merck & Co. Inc. (MRK) was downgraded to B from B+ on 12/4/2014 due to a decline in the solvency index, valuation index and dividend index.
Merck & Co. Inc. (MRK) was downgraded to B from B+ on 12/4/2014 due to a decline in the solvency index, valuation index and dividend index.
B
Buy
11/12/2014Downgrade
Merck & Co. Inc. (MRK) was downgraded to B+ from A- on 11/12/2014 due to a major decline in the growth index, volatility index and valuation index. Earnings per share declined from $0.68 to $0.31, and total revenue declined 3.45% from $10.93B to $10.56B.
Merck & Co. Inc. (MRK) was downgraded to B+ from A- on 11/12/2014 due to a major decline in the growth index, volatility index and valuation index. Earnings per share declined from $0.68 to $0.31, and total revenue declined 3.45% from $10.93B to $10.56B.
A
Buy
8/8/2014Upgraded
Merck & Co. Inc. (MRK) was upgraded to A- from B on 8/8/2014 due to a significant increase in the growth index, volatility index and valuation index. Earnings per share increased from $0.57 to $0.68, total revenue increased 6.53% from $10.26B to $10.93B, and EBIT increased 3.93% from $2.27B to $2.35B.
Merck & Co. Inc. (MRK) was upgraded to A- from B on 8/8/2014 due to a significant increase in the growth index, volatility index and valuation index. Earnings per share increased from $0.57 to $0.68, total revenue increased 6.53% from $10.26B to $10.93B, and EBIT increased 3.93% from $2.27B to $2.35B.
NYSE
12/01/2023 4:00PM Eastern
Quotes delayed
